Black Friday Savings ! Exclusive Deals on Latest Pharma and Medical Technology Reports.
Explore NowDelveInsight’s, “Familial Adenomatous Polyposis– Pipeline Insight, 2021,” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Familial Adenomatous Polyposis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Familial Adenomatous Polyposis: Overview
Familial Adenomatous Polyposis is a serious, life-threatening, genetic disorder and is characterized by the initial development of many tens to thousands of adenomas in the rectum and colon during the second decade of life. FAP is caused by a germ line mutation of the adenomatous polyposis coli (APC) gene. The inheritance of FAP is autosomal dominant. FAP causes extra tissue (polyps) to form in large intestine (colon) and rectum. Polyps can also occur in the upper gastrointestinal tract, especially the upper part of small intestine (duodenum). If untreated, the polyps in the colon and rectum are likely to become cancerous.
Symptoms
The symptoms of Familial Adenomatous Polyposis include:
Diagnosis
A diagnosis of Familial Adenomatous Polyposis is made based upon a thorough clinical evaluation, a detailed patient history, and a variety of specialized tests. Screening is done using sigmoidoscopy, colonoscopy, esophagogastroduodenoscopy (EGD) and side-viewing duodenoscopy. CT or MRI imaging of the abdomen and pelvis may be used, especially to evaluate desmoid tumors. Genetic testing can confirm the mutation and disease.
Treatment
Treatment of FAP Patients are managed through regular endoscopic surveillance. Polyps are controlled by polypectomy or ablation. Surgical options include: Colectomy with ileo-rectal anastomosis, Proctocolectomy with ileal pouch anal anastomosis Proctocolectomy with permanent ileostomy. A combination of medications, including nonsteroidal anti-inflammatory drugs, anti-estrogen and chemotherapy is provided for desmoid tumors. Research is continue to evaluate additional treatments for FAP. Medications like sulindac (Clinoril®) and celecoxib (Celebrex®) have been shown to reduce the number of colorectal polyps and delay the timing of the first surgery. These medications can also control polyps in the pouch or rectum after surgery, or the need for additional surgeries.
This segment of the Familial Adenomatous Polyposis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Familial Adenomatous Polyposis Emerging Drugs
ALFA: SLA Pharma
ALFA is an experimental drug that is an arachidonic acid modulators. Alfa is currently in a Phase 3 clinical trial to assess the efficacy and safety of eicosapentaenoic acid free fatty acid (EPA-FFA) for patients with Familial Adenomatous Polyposis & ulcerative colitis (UC).
eRapa: Emtora Biosciences
eRapa (Sirolimus) is a proprietary, patented, micro-encapsulated formulation of rapamycin that protects the active ingredient from rapid, low pH degradation in the stomach. The eRapa (encapsulated rapamycin) drug product consists of sub-micron rapamycin particles incorporated into poly (methyl methacrylate) polymer (Eudragit® L 100 / S 100). eRapa modulates the mTOR pathway, which controls cell growth, proliferation, nutrient transport, autophagy, and survival.
Further product details are provided in the report……..
This segment of the report provides insights about the different Familial Adenomatous Polyposis drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 12+ key companies which are developing the therapies for Familial Adenomatous Polyposis. The companies which have their Familial Adenomatous Polyposis drug candidates in the most advanced stage, i.e. phase III include, SLA Pharma.
DelveInsight’s report covers around 12+ products under different phases of clinical development like
Familial Adenomatous Polyposis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Familial Adenomatous Polyposis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Familial Adenomatous Polyposis drugs.
Current Treatment Scenario and Emerging Therapies:
Introduction
Executive Summary
Familial Adenomatous Polyposis : Overview
Pipeline Therapeutics
Therapeutic Assessment
Familial Adenomatous Polyposis– DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Familial Adenomatous Polyposis Collaboration Deals
Late Stage Products (Phase III)
ALFA: SLA Pharma
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
eRapa: Emtora Biosciences
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Guselkumab: Janssen Biotech
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Eflornithine/sulindac conjugate: Cellix Bio
Drug profiles in the detailed report…..
Inactive Products
Familial Adenomatous Polyposis Key Companies
Familial Adenomatous Polyposis Key Products
Familial Adenomatous Polyposis - Unmet Needs
Familial Adenomatous Polyposis - Market Drivers and Barriers
Familial Adenomatous Polyposis - Future Perspectives and Conclusion
Familial Adenomatous Polyposis Analyst Views
Familial Adenomatous Polyposis Key Companies
Appendix
List of Table
Table 1: Total Products for Familial Adenomatous Polyposis
Table 2: Late Stage Products
Table 3: Mid Stage Products
Table 4: Early Stage Products
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Product Type
Table 7: Assessment by Stage and Product Type
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: Inactive Products
List of Figures
Figure 1: Total Products for Familial Adenomatous Polyposis
Figure 2: Late Stage Products
Figure 3: Mid Stage Products
Figure 4: Early Stage Products
Figure 5: Preclinical and Discovery Stage Products
Figure 6: Assessment by Product Type
Figure 7: Assessment by Stage and Product Type
Figure 8: Assessment by Route of Administration
Figure 9: Assessment by Stage and Route of Administration
Figure 10: Assessment by Molecule Type
Figure 11: Assessment by Stage and Molecule Type
Figure 12: Inactive Products
• Emtora Biosciences
• SLA Pharma
• Cancer Prevention Pharmaceuticals
• Janssen Biotech
• Cellix Bio
• Zikani Therapeutics
• TherapyX
• FunPep
